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Pharmacological therapy is essential in many diseases treatment and it is important that the medicine 
policy is intended to offering safe and effective treatment with affordable price to the population. One 
way to achieve this is through biowaiver, defined as the replacement of in vivo bioequivalence studies 
by in vitro studies. For biowaiver of new immediate release solid oral dosage forms, data such as 
intestinal permeability and solubility of the drug are required, as well as the product dissolution. The 
Biopharmaceutics Classification System (BCS) is a scientific scheme that divides drugs according to 
their solubility and permeability and has been used by various guides as a criterion for biowaiver. This 
paper evaluates biowaiver application, addressing the general concepts and parameters used by BCS, 
making a historical account of its use, the requirements pertaining to the current legislation, the benefits 
and risks associated with this decision. The results revealed that the use of BCS as a biowaiver criterion 
greatly expands the therapeutics options, contributing to greater therapy access of the general population 
with drug efficacy and safety guaranteed associated to low cost.
Uniterms: Medicines/biowaiver. Biopharmaceutics Classification System. Drugs/solubility. Drugs/
permeability. Drugs/dissolution. Drugs/legislation.
O tratamento farmacológico é essencial frente a várias patologias e é fundamental que a política de 
medicamentos tenha por objetivo oferecer à população tratamento seguro, eficaz e de preço acessível. 
Uma forma de alcançar esse objetivo é por meio da bioisenção, definida como a substituição de 
estudos de bioequivalência in vivo por estudos in vitro. Para bioisentar novos medicamentos sob a 
forma farmacêutica sólida oral de liberação imediata são utilizados dados de permeabilidade intestinal 
e solubilidade do fármaco, bem como sua dissolução a partir da forma farmacêutica. O Sistema de 
Classificação Biofarmacêutica (SCG) é um esquema científico que divide os fármacos em classes de 
acordo com solubilidade e permeabilidade e vem sendo utilizado como critério para bioisenção em 
diversas legislações. O presente artigo faz uma avaliação desta utilização, abordando os conceitos 
gerais e parâmetros utilizados pelo SCB, fazendo um relato histórico da aplicação da bioisenção, das 
exigências pertinentes às legislações vigentes, dos benefícios e riscos inerentes a uma tomada de decisão 
sobre bioisenção baseada neste critério. Os resultados revelaram que a utilização do SCB como critério 
amplia enormemente as possibilidades de bioisenção, contribuindo para o maior acesso da população 
em geral a medicamentos com garantida eficácia, segurança e menor custo.
Unitermos: Medicamentos/bioisenção. Sistema de Classificação Biofarmacêutica. Fármaco/solubilidade. 
Fármaco/permeabilidade. Fármaco/dissolução. Fármaco/legislação.
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INTRODUCTION
Medicines are the most important tool that society 
possesses to prevent, alleviate and cure diseases (Leach, 
Palluzi, Munderi, 2005). However, about 30% of the world 
population has no access to effective, safe and quality 
medicines,and more than half of those live in developing 
countries in Africa and Asia (WHO, 2004).This problem 
is so serious that in 2000 the United Nations (UN), 
analyzing the major problems of the world, established 
the Millennium Program, where 191 countries signed 
an agreement with 8 goals and 18 targets that must be 
achieved until 2015. One of these goals is to provide 
access to quality essential medicines at affordable prices 
(Brasil, 2007).
Several factors influence people’s access to 
medicines and it is necessary a national policy to regulate 
and monitor these several factors. Among those we may 
cite: a system for efficient drug selection and free from 
pressures, a policy of public funded sustainable system 
for regulating the drug market, controlling overtaxes 
and other factors that impact on prices, as well as an 
efficient distribution system (Leach, Palluzi, Munderi, 
2005).
In this sense, the policy of generic medicines is 
an important strategy for increasing access to essential 
medicines, particularly in developing countries by 
reducing costs, both for the consumer as for purchase 
by the public system, for subsequent distribution to the 
population.
Some defined dosage forms of generic medicines 
must necessarily prove its bioequivalence in relation to 
the reference product (Miranda et al., 2009). This testing 
assess the intensity and extent of absorption in humans 
and to do this, the costs are high, inherent to the clinical, 
analytical and statistical steps that consume the time of 
3 to 7 months between the selection of which center will 
elaborate the studies, approval by the ethics committee 
on research, development and selection of volunteers for 
those steps. However, this provides consumers with the 
opportunity to purchase medicines at more affordable 
prices, with a guarantee of quality, safety, efficiency and 
interchangeability with the reference medicines (Araújo 
et al., 2010; Melo, 2005).
The Food and Drug Administration (FDA), the U.S. 
regulatory agency, estimates that in coming years, US$ 
60 to US$ 70 billion in branded medicines will lose their 
patent protection (United States, 2007). This means that 
these drugs may be considered to be registered as generic, 
but for this, it is necessary knowledge and structure able 
to respond quickly to a potential increase in demand for 
generic drugs registration. In order to do that, biowaiver 
can be a good tool and thus bring benefits to the society 
by expanding the supply of medicines effective with 
guaranteed security. The biowaiver can be defined as 
the acceptance for regulatory purposes, of the exemption 
or replacement of in vivo bioequivalence studies and 
bioavailability by in vitro assays when they are able to 
replace the in vivo assay reliably (Storpirtis, Gai, 2009). 
The registration process through biowaiver enables a 
reduction in the exposure of volunteers in clinical studies, 
time and cost of product development with quality 
and safety certified (Lennernäs, Abrahamsson, 2005). 
Therefore, the biowaiver brings considerable benefits for 
the patient and government health systems. In Brazil, it 
is an important contribution to the national health system 
(SUS) in terms of access to drug treatment. The Food and 
Drug Administration and Agência Nacional de Vigilância 
Sanitária (ANVISA) that is the Brazilian regulatory 
agency, use the Biopharmaceutics Classification System 
(BCS) as a mean to allow biowaiver of Immediate-
Release Solid Oral Dosage Forms containing drugs 
with high solubility and permeability (BCS Class I) 
(United States, 2000 Brasil, 2011). The European Union 
agency (EMA) responsible to indicate candidates to 
biowaiver has considered eligible the class I of BCS 
and additionally, drugs which have high solubility and 
low permeability (BCS Class III), when they show very 
rapid dissolving (85% in 15 minutes). The World Health 
Organization (WHO) further extends the applicability of 
biowaiver for drugs in classes I, III and also drugs poorly 
soluble and highly permeable (Class II), when they have 
characteristics of weak acid and high solubility in pH 6,8, 
besides rapid or very rapid dissolving (EMEA, 2008; 
WHO, 2006).
This article aims to contribute to the understanding 
of the general concepts on the topic and discuss the 
inclusion of BCS as a biowaiver criterion. Moreover, it 
presents the historical account of the relevant legislation, 
effective criteria to apply biowaiver and discusses the 
benefits and risks of using the BCS as a regulatory tool.
METHODS
The laws related to biowaiver were checked at sites 
of the regulatory agencies of interest, ANVISA (http://
www.anvisa.gov.br/e-legis), FDA (http://www.fda.gov/
default.htm) and EMA (http://www.ema.europa.eu/ema/), 
to evaluate the inclusion of BCS as a criterion to enable 
biowaiver. Additionally, we carried out search of scientific 
basis for allowing the presentation and discussion of 
the laws cited. With this goal bibliographic data bases 
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PubMed (www.ncbi.nlm.nih.gov), Scopus (www.scopus.
com/home.url) and SciELO (www.scielo.org) were 
consulted from November 2011 to February 2014, using 
the following search terms: biowaiver, BCS, permeability 
and solubility.
THEORETICAL BASIS FOR BIOWAIVER
Biopharmaceutical classification system
The Biopharmaceutical Classification System is a 
scientific schematic proposed by Amidon and coworkers 
in 1995, which allowed the classification of drugs based 
on solubility and intestinal permeability parameters in four 
classes (Amidon et al., 1995).
The four possible categories for a drug according to 
the BCS are in Table I
The solubility and intestinal permeability are 
among the main factors that govern the rate and extent 
of drug absorption and therefore are directly related to 
bioavailability (Amidon et al., 1995).
The insertion of the BCS as a criterion for biowaiver 
started in FDA guide, also being currently accepted 
by ANVISA and EMA. This addition allowed the 
simplification of registration of new medicines according 
to Abbreviated New Drug Application (ANDA) in USA 
(Löbenberg, Amidon, 2000).
Solubility
By definition, solubility is the extent to which one 
molecule of a solid is removed from its surface by a solvent 
(Martinez, Amidon, 2002) being a determining factor for 
the absorption and bioavailability of active compounds 
(Panchagnula, Thomas, 2000).
A drug is considered highly soluble when the highest 
dose administered as an immediate release formulation, is 
soluble in 250 ml or less of aqueous media with a pH in a 
range of 1.2 to 6.8 at 37±1 °C (Brasil, 2011).
Permeability
The permeability is a dynamic and complex process 
that involves the permeation of the drug across biological 
membranes. The arrival of the drug into the bloodstream is 
made by the absorption pharmacokinetics processes. The 
transport mechanisms include passive diffusion through 
the enterocytes (transcellular) and the junctions between 
the enterocytes (paracellular) as well as active mechanisms 
employing energy and carriers (Balimane et al., 2000).
A drug is considered highly permeable when the 
extent of absorption in humans is 85% (Brasil, 2011; 
EMEA, 2008; WHO, 2006) or more, based on mass balance 
determination or in comparison with an intravenous dose. 
On the other hand, according to FDA (2000) one drug is 
classified as highly permeable when the fraction of the 
absorbed dose or the absolute bioavailability is equal 
or greater than 90%. This criterion can be considered 
conservative because there are many reports of drugs that 
are generally considered well or completely absorbed, 
that present fraction of absorbed dose less than 90%. This 
suggests that a threshold rating of 85% may be appropriate 
in the definition of high permeability (Yu et al., 2002).
The need to obtain data relating to intestinal 
permeability of drugs has raised the development of 
various models for the determination of permeability, 
which may be in vivo, in situ, in vitro and in silico (Souza, 
Freitas, Storpirtis, 2007). The methods continue to be 
improved and it is recommended that conclusions should 
be obtained by using more than one method (Balimane et 
al., 2000).
Dissolution
The dissolution can be defined in a narrow sense as 
the process by which a solid substance enters the solvent to 
form a solution. However, in the broad sense of the word, 
it is more than simply measuring the rate of solubility and 
can be more correctly described as a physical assay to 
predict the release of substance for a given area, in quantity 
and adequate time (Manadas, Pina, Veiga, 2002).
The absorption of a drug contained in solid dosage 
form after oral administration depends on its release, 
solubilization and dissolution under physiological 
conditions and posterior permeability through the 
gastrointestinal tract. The first two steps present a critical 
nature and therefore, in vitro dissolution may be relevant 
to predict the in vivo performance. In vitro dissolution 
tests for oral solid dosage forms such as tablets and 
capsules are used to: [1] assess the quality of a batch to 
batch drug; [2] guide development of new formulations; 
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[3] guarantee the maintenance of product quality after 
certain changes in the design, process, and on site 
production scale (United States, 1997) and [4] assess 
the pharmaceutical equivalence between products from 
different manufacturers (Rodrigues et al., 2006).
One way to evaluate the dissolution is by determining 
the dissolution profile, graph of percentage of drug 
dissolved versus time, which is a relatively quick and 
inexpensive way to evaluate solid dosage forms and allows 
obtaining kinetic parameters. These are important for 
determining the speed and efficiency of the process and 
the time needed for specific release of drug percentages, 
allowing conclusions about in vitro biopharmaceutical 
characteristics of the formulation (Storpirtis et al., 1999).
Pharmaceutical Equivalence
Pharmaceutical equivalence between two medicines 
is related to the confirmation that both contain the same 
drug (same basis, salt or ester of the same therapeutically 
active molecule) at the same dose and dosage form, and 
may be evaluated through in vitro tests (Storpirtis et al., 
2004). To be considered pharmaceutical equivalents, 
the test and reference medicine must comply in full 
with the requirements of pharmacopoeia monographs, 
completed with assays described in general methods for 
the pharmaceutical form (Brasil, 2010).
Bioequivalence/Relative Bioavailability
Bioequivalence or relative bioavailability is the 
comparative study of products containing the same 
drug administered by the same route. Two products are 
considered bioequivalent if, when administered to the 
same individual under the same experimental conditions 
and at the same molar dose do not differ significantly from 
the amount of drug absorbed and the rate of absorption 
process (Storpirtis, Consiglieri, 1995).
Brazilian law states that for a drug to be registered 
as generic, it is necessary to prove their pharmaceutical 
equivalence and bioequivalence in respect to the 
reference product indicated by ANVISA (Brasil, 2003a). 
As for similar drugs products, it is required to prove 
pharmaceutical equivalence and similar relative 
bioavailability to the inclusion of a new product or 
renewal of registration of drugs already on the market 
(Brasil, 2003b).
For the registration of similar medicines in Brazil, 
up to the year 2003, it was not necessary the proof 
of bioavailability. According to RDC N.134/2003 
the new reality of achieving this requirement must 
occur until 2014. For this process, ANVISA adopted 
“Relative bioavailability” for similar medicines as 
a term to differentiate them from generic medicines 
(interchangeable), since the term “bioequivalence” is 
established and accepted internationally for generic 
products (Araújo et al., 2010).
BIOWAIVER
A Biowaiver means that relative bioavailability and/
or bioequivalence tests are not required for the registration 
of a medicine by the regulatory authority, when a suitable 
in vitro assay can replace it (Brasil, 2011).
The main reason for biowaiver based on the BCS 
is that in some situations, in vitro assays are as good as 
in vivo tests to determine the bioequivalence of oral solid 
dosage forms and sometimes better in terms of direct 
evaluation of product performance. Moreover, biowaiver 
eliminates unnecessary exposure of healthy subjects to in 
vivo studies, reduces the burden of evaluating petitions for 
registration requiring BE studies, and provides economic 
relief, maintaining the quality standard of dispensed 
medicines to public health and thus ensuring therapeutic 
equivalence (Cook et al., 2010).
An estimated 66 to 76 million dollars can be saved 
each year in costs of clinical studies if biowaiver is granted 
to all applications for new drugs containing drug class I. If 
this is extended to class III compounds, additional savings 
from 62 to 71 million dollars can be performed (Cook et 
al., 2010).
BCS AS BIOWAIVER CRITERION
The first legislation of biowaiver which includes the 
BCS as a criterion and that is still in use, was published 
by the FDA in August 2000. This exemption would be 
based on the grounds that, if two formulations present the 
same dissolution profile in vivo, under the same conditions 
of the intestinal lumen, they present the same profile of 
concentration versus time on the surface of the intestinal 
membrane, which results in the same rate and extent of 
absorption (United States, 2000).
ANVISA, as well as FDA, in its recently published 
guide, RDC Resolution No. 37, August 3, 2011 (Brazil, 
2011), recommends the exemption of bioavailability/ 
bioequivalence studies in cases of drugs highly soluble 
and highly permeable (Class I) into oral solid dosage forms 
that provide rapid dissolving, in other words, not less than 
85% in 30 minutes. Moreover, evidence of solubility, 
permeability and dissolution should be performed 
according to the methods proposed in the legislation 
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(United States, 2007; Brasil, 2011).The normative 
statement (IN) No.2, (ANVISA, 2013) is a document 
that refers to a list of drugs whose biopharmaceutical 
characteristics were established and are suitable to pass 
by the biowaiver process according to RDC Resolution 
No. 37, August 3, 2011.
In Europe, the EMA published in 2001 its biowaiver 
guide, which was updated in 2008. In this resolution, FDA 
and ANVISA recommend the BCS biowaiver in similar 
way, i.e. for medicines containing drugs class I. Besides 
these, EMA also considers the biowaiver based on the 
BCS for class III drugs, i.e. the medicines which have high 
solubility and limited absorption and also have very fast 
in vitro dissolution characteristics (85% in 15 minutes), 
excipients qualitatively and quantitatively identical 
(EMEA, 2008; EMEA, 2001).
In 2006, the World Health Organization (WHO) 
published a document entitled “WHO Technical Report 
Series No. 937” that has an attachment about biowaiver 
theme (“Proposal to waive in vivo bioequivalence 
requirements for WHO Model List of Essential Medicines 
immediate-release, solid oral dosage forms”, Annex 
8). This guide recommends criteria of biowaiver based 
on BCS, however, its requirements are less stringent 
than those set by the guides of the FDA, ANVISA and 
EMA, including drugs of class II, low solubility and high 
permeability, as liable to biowaiver (when they have 
characteristics of weak acid and high solubility in pH 
6,8, besides rapid or very rapid dissolving). The WHO 
recommendation is to establish less conservative criteria, 
especially for well-known drugs, such as those that are part 
of the List of Essential Medicines (WHO, 2006).
In short, according to present guides, for a 
drug to have its biowaiver accepted, it must have its 
biopharmaceutical classification proven, according to 
the criteria of solubility and permeability, as well as 
dissolution characteristics from the dosage form. Table II 
has a comparison of the main requirements for obtaining 
biowaiver based on the BCS, according to regulatory 
agencies ANVISA, FDA, EMA and WHO. In addition, to 
meet these criteria, an analysis of the formulation of the 
biowaiver candidate should also be performed as well as 
a parsing of the risk of an incorrect decision for individual 
and collective health (WHO, 2006; Cook, Addicks, Wu, 
2008).
The quantity of excipients in the IR product should 
be consistent with their intended function. Large quantities 
of certain excipients, such as surfactants (e.g., sodium 
laurylsulfate) or osmotic ingredients (e.g., sorbitol) may 
be problematic and should be avoided except when present 
in the reference drug (United States, 2000).
Since 1977, WHO has periodically prepared a list 
of essential medicines for basic health care. Two studies, 
one conducted by Kasim and colleagues, in 2004, and 
the other held by Lindenberg, Kopp, Dressman, in 2004, 
provisionally classified by the BCS, drugs presented at the 
12th edition of this list (2002). The results of these studies 
have been compiled and presented in Figure 1.
In 2006, Takagi and colleagues (2006) also classified 
by the BCS the 200 best-selling drugs in the United States, 
Spain, Britain and Japan. In short, over 55% of these drugs 
were classified as highly soluble (class I and III), and 
approximately 30% of all drugs contained in oral solid 
dosage forms may be classified as highly soluble and 
highly permeable (Class I).
One of the main initiatives of the FDA regarding 
biowaiver based on BCS was to form a Technical 
Committee to review the requests of biowaiver in March 
of 2004. This committee met six times between 2004 to 
2006 and evaluated 25 requests of biowaiver, 11 for new 
molecules and 14 for generics. Of the 11 requests for new 
molecules analyzed, 7 of them were for drugs of class I and 
had biowaiver accepted. Of the 14 requests for generics 
biowaiver, 9 drugs belonged to class I. Of these, four were 
accepted (Polli et al., 2008).
Biowaiver requests based on BCS were also 
analyzed by EMA, and the following have been accepted 
for biowaiver: phenoxymethylpenicillin, prednisolone, 
transexamico acid, acetaminophen, codeine and ibuprofen 
in Sweden (Graffner, 2006), and sotalol hydrochloride in 
Germany (Alt et al., 2004).
A new approach to ensure a safe decision about 
biowaiver initiated in 2004, by the International 
Pharmaceutical Federation (FIP) that has published 
a number of monographs containing relevant data 
available on literary sources for a given drug. These 
monographs are intended to support the discussion of 
risk associated with biowaiver of certain drugs selected 
by a group of experts from the FIP included in List of 
Essential Drugs. For this proposal, risk is defined as the 
probability of an incorrect biowaiver decision, as well 
as their consequences in terms of public health and risk 
to patients. This initiative has the support of WHO and 
aims especially to assist developing countries, in the 
approval and registration of generic medicines through 
biowaiver (FIP).
In these monographs, a recommendation was made 
about the possibility to biowaiver and although they do not 
have formal regulatory status, represent the best currently 
available scientific opinion. Until 2009, approximately 
26 drugs have been evaluated in these monographs and 
the exemption of in vivo BE was scientifically justified 
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and recommended for the vast majority of them. These 
monographs are part of an ongoing project, and the 
details and progress of this plan are available in www.fip.
org/bcs (Dahan et al., 2009). So far, in 2014, around 40 
monographs dealing with drugs have been written.
BIOWAIVER PETITIONS BASED ON BCS
Although there was an increase in the number of 
applications of biowaiver based on BCS, this progress has 
been tempered by the lack of international harmonization 
and the reluctance of companies to adhere to the 
methodology due to fears raised by a possible delay in the 
registers. Future progress in the use of biopharmaceutical 
in vitro data to substitute in vivo data by bioequivalence 
can also lead to benefits to achieve greater certainty in 
regulatory decisions, e.g. more scientific opportunities to 
discuss the necessary data and successful examples (Polli 
et al., 2008).
As previously mentioned, approximately 30% of 
all drugs contained in oral solid dosage forms may be 
classified as highly soluble and highly permeable (Takagi 
et al., 2006). So it may be surprising that, between 2003 
and 2006, only 25 requests (11 for new drugs and 14 for 
generics) were submitted to the FDA for exemption from 
an in vitro study based on biopharmaceutical classification. 
The perceived lack of certainty of the acceptance by 
TABLE II - Main requirements for obtaining biowaiver based on BCS
REGULATORYAGENCY
FDA ANVISA EMA OMS
Candidates according to 
BCS Class I Class I and III** Class I, II* e III**
Characteristic for high 
solubility classification 
of drugs
Higher dose commercially 
available must be soluble 
in ≤ 250 mL, pH 1-7.5, 
37 °C
Highest single dose administered to the patient and provided in package 
insert must be soluble in ≤ 250 mL,pH 1.2 to 6.8, 37 ⁰C.
Classification of high 
permeability drugs
Superior to metoprolol 
absorption (absorption≥ 90 
% of administered dose)
Absorption ≥85%
Dissolution media buffer pH1.2, 4.5 and 6.8; 37 °C
Volume of medium 900 mL 500 mL 900 mL
Apparatus and rotation Paddle: 50 rpm/Basket: 100 rpm. Paddle: 75 rpm/ Basket: 100 rpm.
Dissolution profile I:Rapid dissolving
I: Rapid dissolving 
III: Very rapid 
dissolving
I: Rapid dissolving 
II: Rapid dissolving 
at pH 6,8 




Excipients used in 
the dosage form must 
have been used in a 
previously approved 
immediate release (IR) 
solid oral dosage form 
by the Food and Drug 
Administration .
Qualitatively the same 
and quantitatively very 
similar to the respective 
reference drug product
Absence of excipients 
that have an impact on 
bioavailability.
* Weak acid, high solubility in pH 6,8, rapid or very rapid dissolving. ** Very rapid dissolving (85% in 15 minutes)
FIGURE 1 - Provisional Classification of drugs present in the 
12th edition of the essential drugs list proposed by Kasim et al. 
(2004) and Lindenberg, Kopp, Dressman (2004).
Biopharmaceutics classification system: importance and inclusion in biowaiver guidance 149
regulatory agencies of biowaiver requests based on BCS 
has been cited as one reason for the small number of 
requests by pharmaceutical industry (Polli et al., 2008).
Despite agencies like the FDA undertake significant 
efforts to promote the use of biowaiver based BCS, 
the time between the submission of an application for 
biowaiver and the formal approval needs to be fast enough 
(e.g., within weeks instead months), to have the adhesion 
of pharmaceutical companies. Not granting the biowaiver 
approval can lead to a significant delay in the development 
program of a new pharmaceutical product. Initially, the 
risk associated with receiving a negative response from 
biowaiver seemed greater than the benefits of economy 
of resources (Cook, Addicks, Wu, 2008). Nowadays, 
greater disclosure procedures for testing solubility and 
permeability as well as the expansion and dissemination 
of studies of drugs that could be waiver of bioequivalence 
studies contributes to expanding the adherence of the 
pharmaceutical industry (ANVISA, 2013; Cristofoletti 
et al., 2013).
Another barrier to the application of biowaiver 
refers to compartmentalization of some large companies, 
which can cause doubt as to the allocation of financial 
resources and the allocation of responsibilities regarding 
the success or failure of the biowaiver request. In the first 
case, the values saved by an organization resulting from 
a biowaiver typically appear in the clinical department 
budget. However, departments such as preclinical 
pharmacokinetic, chemistry and formulation may be 
required to perform more than the normal amount of work 
to support the application of a biowaiver. As a result, 
there may be reluctance by all parts of the organization to 
support a strategy for biowaiver. In the second case, the 
difficulty to employ biowaiver based on BCS can also be 
caused by lack of clarity on the responsibility to generate 
documents for biowaiver and to the attribution of blame, 
if a request of biowaiver is rejected and the time to launch 
a new product is delayed (Cook, Addicks, Wu, 2008).
DISCUSSION
The BCS developed by Amidon et al. (1995) aimed 
to employ specific tests in vitro in order to predict the drugs 
dissolution and therefore to estimate the results of their 
bioavailability (BD) in vivo, produced a significant impact 
on drug policy, making it possible to exempt BD and BE 
tests in vivo for class I drugs in oral solid dosage forms 
(FDA, EMA, ANVISA and WHO) for class III (EMA 
and WHO) and for a specific group of class II compounds 
(WHO). This is highly relevant for the possible decrease 
in the costs for registration of new generic drugs (Ramirez 
et al., 2010).
However, as shown in Figure 1, there are drugs in 
the WHO essential drugs list that have not been classified 
according to the BCS. This is because of the difficulty 
in obtaining permeability data, determined in vivo by 
absolute bioavailability or using in vitro, in silico and ex 
vivo models. Although for the registration of new drugs is 
necessary to define the absolute bioavailability, this is not 
usually easily accessible. As regards the other applicable 
models difficulties of standardization of methodologies, 
reproducibility of results and inconsistency with in vivo 
data are observed (Souza, Freitas, Storpirtis, 2007).
There are some criticisms of the use of BCS that 
fail in taking into account the dynamic system that 
occurs in vivo. An example of this is non-steroidal 
anti-inflammatory drugs that are classified as II and 
show extensive absorption. The biopharmaceutics drug 
disposition classification system (BDDCS), an alternative 
to the BCS, was proposed by Benet and collaborators 
(2008). It classifies drugs using aqueous solubility and 
metabolism (for the classification of permeability). This 
system aims to explain the results of BD in vivo for drugs 
with high permeability and also extensive metabolism. 
The correlation between metabolism and permeability 
can be explained in the case of drugs BCS of class I and 
II (highly permeable) that are able to reach the metabolic 
enzymes in hepatocytes. On the other hand, there are 
also limitations to BDDCS, among which the need of a 
suitable methodology that is able to predict the effect of 
the formulation components on the intestinal transporters. 
An example of the discrepancy of the results is sotalol, 
which has low liver metabolism, absorption less than 90%, 
and is approved by the FDA as Class I (Benet et al., 2008; 
Chen, Yu, 2009).
The same occurs to solubility data, although 
available in greater number in the literature, were 
not always obtained from experiments performed in 
accordance to biowaiver requirements as the means and 
temperature appropriate (Table I) (Lindenberg, Kopp, 
Dressman, 2004).
Furthermore, the BCS must be selectively used and 
considering carefully regulatory risks versus the benefits 
for a possible biowaiver. In particular, for compounds that 
do not have clarity on permeability data from the literature, 
the potential risk of rejection of the permeability study 
submitted or a potential delay due to issues that may arise 
during the review of the data, must be weighed against 
time and costs required to conduct a bioequivalence study 
(Cook, Addicks, Wu, 2008). It should also be demonstrated 
that the excipients included in the new formulation are well 
established for use in products containing such drug. These 
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pharmaceutical adjuvants should not cause differences 
between the reference product and the generic candidate 
product in in the terms of affecting the absorption process, 
or other pharmacokinetic processes (WHO, 2006).
Noteworthy, the demonstration of bioequivalence 
is the biggest concern for the approval and use of generic 
products, and the possibility of a biowaiver for in vivo 
bioequivalence studies must be approached with caution 
and careful supervision to ensure the safety and efficacy 
of these drugs (Ramirez et al., 2010).
In practice, a universalization of the benefits of 
biowaiver based on BCS is not expected due to the 
existence of differences in regulations worldwide. For 
example, while the United States (FDA, 2000), the 
European Union (EMEA, 2008), Brazil (Brasil, 2011) and 
WHO (2006) allow biowaiver based on dissolution and 
classification by BCS, Japan does not allow it (Yamashita, 
Tachiki, 2008). At this point, the FDA’s and EMA´s guide 
and the proposed requirements by WHO for biowaiver also 
show discrepancies in the definitions of high solubility 
(pH of 7.5 in the FDA’s guide and 6.8 in EMA’s guide 
and WHO proposal) and high permeability (the criterion 
of 90% on FDA’s guide and 85% in the WHO proposal 
and EMA’s guide) (Ramirez et al., 2010). Consequently, 
this leads to global pharmaceutical companies choosing to 
demonstrate the bioequivalence using a methodology that 
will enable acceptance by most countries. In general, there 
is a historical reluctance of these companies in continuing 
with biowaiver based on BCS due to uncertainty as to the 
success in their petitions to the various regulatory agencies 
(Cook et al., 2010).
The new drugs biowaiver employing the criterion 
of the BCS, according to Brazilian and U.S. regulations is 
indicated for solid oral dosage forms of immediate release, 
whose drugs are Class I (Brasil, 2011). It is also desirable 
that they are stable in the gastrointestinal tract, have wide 
therapeutic range, are not absorbed in the oral cavity, 
present low risk, their formulations contain excipients 
that do not significantly affect the rate and extent of 
oral absorption. Drugs are considered low-risk are the 
ones for which there are no reports of bioavailability or 
bioequivalence problems (United States, 2000).
According to the guidelines of WHO and EMA, 
Class III drugs can be included in the list of candidates 
for biowaiver. For this class, permeability is the factor that 
controls the absorption, so care should be taken since the 
rate and extent of absorption can be highly variable. The 
dissolution profile of the formulation should be clearly 
defined and reproducible (EMEA, 2008; WHO, 2006; 
Tsume, Amidon, 2010; Reddy, Karunakar, 2011).
For WHO, class II drugs are also likely biowaivers 
if they are weak acids showing high solubility at pH 6.8 
and present, rapid or very rapid dissolving. For this class 
the limiting step of absorption is dissolution in vivo, 
thus the dissolution profile should be clearly defined 
and reproducible, emphasizing the importance of using 
methods that reflect or control the dissolution process in 
vivo (WHO, 2006; Alvarez et al., 2011).
Cristofoletti and colleagues (2013) calculated 
the diagnostic indicators utilizing 22 results of in vitro 
dissolution profiles performed at neutral conditions 
(phosphate buffer under pH 6.8-7.5) for a set of eight non-
BE (all of them because of Cmax) and 14 BE drug products 
containing five weak acidic drugs, with pKa of less than 
5.5 and which have dose numbers lower than one at pH 
values ranging from 6.8 to 7.4. However, these diagnostic 
parameters not were different from those calculated for all 
drugs belonging to BCS class II, in accordance with the 
previous reports for drug products containing ibuprofen 
that showed that dissolution tests, under neutral conditions, 
were unable to detect differences in absorption rate.
To minimize the risk of an incorrect decision about 
biowaiver in terms of public health and of individual risks 
to patients, the therapeutic indications of the drug, its 
pharmacokinetic variations, interactions with food, and 
other factors, should be evaluated (Mehta, 2007).
Exceptionally, excipients can have an impact on in 
vivo permeability, either directly in the active or passive 
passage of the drug through the gut wall or indirectly by 
altering the gastrointestinal transit time/residence time. The 
possible appearance of these effects is a risk that should not 
be ignored, but are relatively rare, and tend to require many 
specific high risk excipients to cause significant change in 
vivo (Butler, Dressman, 2010). It should be emphasized that 
a description of excipients is required, with a justification if 
the amount of each excipient is within the range considered 
normal. The so called active excipients such as, for example, 
sorbitol, mannitol, sodium lauryl sulfate or other surfactant 
must be identified when present in the medicine as well 
as their possible impact with respect to: gastrointestinal 
motility, sensitivity interaction with the drug, the drug 
permeability and interaction with membrane transporters. 
In those cases where critical excipients are relevant, the 
same amount should be used in both reference and generic 
products (EMEA, 2008).
CONCLUSION
One of the current applications of BCS is to supply 
means to provide biowaiver of new generic medicines 
containing drugs belonging to Class I (FDA, EMA, 
WHO and ANVISA), class III (EMA and WHO) and a 
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specific group of compounds of class II (WHO). Granting 
of biowaiver based on criteria such as BCS eliminates 
unnecessary exposure of healthy individuals to drugs, 
reduces the regulatory burden, and provides economic 
relief, maintaining the high standard of public health for 
therapeutic equivalence (Cook et al., 2010). Especially in 
developing countries, where there are often insufficient 
resources to achieve the bioequivalence studies, the use of 
BCS becomes an important tool to ensure the efficiency 
and quality of pharmaceutical products (Benet et al., 2008).
In this article, it was found that the BCS, greatly 
expands the possibilities of biowaiver, contributing to give 
greater flexibility to the registration of generic medicines of 
assured efficacy and safety, thus providing increased supply 
of affordable treatment options, which meets the public 
policy expanding access to medicines to the population. 
Since the politic of generics was deployed in Brazil, in 
1999, a huge amount of investment has been made in 
order to inform people that the generic products pass by 
bioequivalence test and they are as effectives and safe as the 
reference drug. In 2014, it was proposed that similar drugs 
are interchangeable with the reference drugs. According to 
the proposal, similar packaging hall include in its brand, 
“equivalent product”, symbolized by the acronym “EQ”. 
The brand will enable consumers and physicians to identify 
products that have proof of equivalence and perform the 
same therapeutic function in relation to the reference 
(ANVISA, 2014). Therefore, it should be emphasized that a 
safe biowaiver decision should be made scientifically based 
on adequate and reliable experimental data, aiming not to 
put this politics into disrepute.
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